Yili Chuanning Biotechnology Earnings Call Summary
Earnings Call Summary
A brief overview of the key points discussed during a company’s quarterly earnings call, including financial performance, guidance, and management’s commentary on future outlook.
Yili Chuanning Biotechnology Earnings
Estimates
Actual
Y-on-Y Change
Revenue
EPS
Transcripts
Events
About Yili Chuanning Biotechnology Co.,Ltd.
Yili Chuanning Biotechnology Co.,Ltd.
301301
Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxycholic acid; coenzyme Q10 mycelia; and other products. It also provides synthetic biology products, including bisabolol, 5-hydroxytryptophan, ergothioneine, ekdoin, inositol, squalane, polyhydroxyalkanoate (PHA), and phytosphingosine. In addition, the company engages in trading, crop planting, inspection, technical advisory, and asset investment activities. The company was incorporated in 2010 and is based in Yining, China. Yili Chuanning Biotechnology Co.,Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates c...
Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxycholic acid; coenzyme Q10 mycelia; and other products. It also provides synthetic biology products, including bisabolol, 5-hydroxytryptophan, ergothioneine, ekdoin, inositol, squalane, polyhydroxyalkanoate (PHA), and phytosphingosine. In addition, the company engages in trading, crop planting, inspection, technical advisory, and asset investment activities. The company was incorporated in 2010 and is based in Yining, China. Yili Chuanning Biotechnology Co.,Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
No. 1 Gongchen Road, Yining Park, Economic Development Zone, Horgos City, Ili Kazakh Autonomous Prefecture, Yining, Xinjiang Uygur Province, 835000, China
Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach. Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.